Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Show more...
FAQ
Argenica Therapeutics Limited 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 OTC MARKETS 交易所,Argenica Therapeutics Limited 的股票以代號 AGNTF 進行交易。
Argenica Therapeutics Limited 去年的營收是多少?▼
Argenica Therapeutics Limited 去年的營收為 0USD。
Argenica Therapeutics Limited 去年的淨利是多少?▼
AGNTF 去年的淨收益為 -3.68MUSD。
Argenica Therapeutics Limited 有多少名員工?▼
截至 September 05, 2026,公司共有 7 名員工。
Argenica Therapeutics Limited 位於哪個產業?▼
Argenica Therapeutics Limited從事於Health & Wellness產業。
Argenica Therapeutics Limited 何時完成拆股?▼
Argenica Therapeutics Limited 最近沒有進行任何拆股。
Argenica Therapeutics Limited 的總部在哪裡?▼
Argenica Therapeutics Limited 的總部位於 澳洲 的 Nedlands。